Clinical Significance: |
Adeno-associated viruses (AAVs) are commonly used in gene therapy due to the ease of genome manipulation, ease of purification and safety (1). However, many AAV serotypes commonly infect humans resulting in pre-existing immunity which may reduce the efficiency of gene therapy that utilizes these serotypes (1,2,3). The AAV9 ELISA detects antibodies against AAV9 which may inhibit the efficacy of gene therapies (1,2).
References:
1. Naso et al. (2017) Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 31(4): 317-334. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548848/
2. Mingozzi and High. (2013) Immune Response to AAV vectors: overcoming barriers to successful gene therapy. Blood. 122(1): 23-26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701904/
3. Boutin et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 21(6): 704-712. https://www.ncbi.nlm.nih.gov/pubmed/20095819
|